Businesswireยท2025-09-22 10:45Company Overview - Pfizer Inc. has entered into a definitive agreement to acquire Metsera, a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases [1][2] - The acquisition is expected to enhance Pfizer's portfolio with differentiated oral and injectable therapies that have potential best-in-class efficacy and safety profiles [1][2] Acquisition Details - Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion [3] - The agreement includes a contingent value right (CVR) that could provide additional payments of up to $22.50 per share based on specific clinical and regulatory milestones [3] Metsera's Portfolio - Metsera has four programs in clinical development, including MET-097i and MET-233i, both of which are injectable GLP-1 receptor agonists [2][4] - The company is also advancing oral GLP-1 RA candidates and additional preclinical hormone therapeutics aimed at addressing unmet needs in obesity treatment [2][4] Strategic Importance - The acquisition aligns with Pfizer's strategy to invest in impactful opportunities within the growing obesity treatment market, which is associated with over 200 health conditions [2] - Pfizer aims to leverage its manufacturing and commercial infrastructure to accelerate the development of Metsera's promising therapeutic candidates [2][5]